By: Lisette Hilton | December 06, 2023 | 4 min. read |
Share
Article Summary
- The LEAF study is the first to show that treating overweight and obese patients with AFib with a combination of risk management strategies and a weight loss drug greatly improved ablation outcomes.
- The study compared groups who received only risk management strategies to those who combined risk management strategies with use of the weight loss drug liraglutide.
- Eighty-three percent of those who implemented both liraglutide and risk management were free of atrial fibrillation after a year, whereas the group that used only risk modification report 57 percent experienced no atrial fibrillation.
Researchers at University of Miami Miller School of Medicine led a study that could result in significantly improved outcomes from ablation used to treat atrial fibrillation (AFib), an irregular heartbeat or arrythmia.
